GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Forward Dividend Yield %

Tourmaline Bio (Tourmaline Bio) Forward Dividend Yield % : 0.00% (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Forward Dividend Yield %?

As of today (2024-05-26), the Forward Annual Dividend Yield of Tourmaline Bio is 0.00%.

As of today (2024-05-26), the Trailing Annual Dividend Yield of Tourmaline Bio is 0.00%.

TRML's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Forward Dividend Yield % only.

Tourmaline Bio's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Tourmaline Bio's Forward Dividend Yield %

For the Biotechnology subindustry, Tourmaline Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Forward Dividend Yield % falls into.


Tourmaline Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Tourmaline Bio  (NAS:TRML) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Tourmaline Bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Forward Dividend Yield %
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.